CDX2 is considered to be a tumor suppressor gene in CRC and patients lacking CDX2 are more likely to develop LNM ( (82)), but whether it has the same value in early CRC needs further research and exploration. This evidence concerns the gene CDX2 and colorectal carcinoma.